"The Administration for Strategic Preparedness and Response’s (ASPR) Center for

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its

Presentation video, PowerPoint slides, and referenced publication: https://journey.ct.events/view/f994d8d6-20e4-4670-8752-ee2696bcf2e6 https://www.cidara.com/wp-content/uploads/2024/08/Cidara-Corporate-Presentation-August-2024-2.pdf https://www.biorxiv.org/content/10.1101/2024.06.04.597465v3.full

The organizational realignment and optimization include phasing out programs in

GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced

Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176

After Moderna last year suffered a loss in its heated

Shortly after winning a stay on a COVID-19 vaccine patent

Cidara Therapeutics (...) today announced that it has entered into

https://www.cidara.com/news/cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advancing-the-clinical-development-of-cloudbreak-dfc-pipeline